Table 3.
Additive KIR/KIR-ligand models
| Classifier | No. of respective patients with AML (No. of total patients with AML) | Portion of respective patients with AML | No. of respective control subjects (No. of total control subjects) | Portion of respective control subjects | P | Adjusted P |
|---|---|---|---|---|---|---|
| Inhibitory KIR/KIR-ligand count considering KIR3DL1/HLA-Bw4 (Boelen et al), overall χ2 test P = .042 | ||||||
| Functional iKIR count (cutoff ≤ 1) | 229 (1 676) | 0.137 | 7 743 (49 898) | 0.155 | .042 | |
| Functional iKIR count (cutoff > 1) | 1 447 (1 676) | 0.863 | 42 155 (49 898) | 0.845 | ||
| Inhibitory KIR/KIR-ligand score considering KIR3DL1/HLA-Bw4 (Boelen et al), overall χ2 test P = .079 | ||||||
| Inhibitory score (cutoff ≤ 1.75) | 674 (1 676) | 0.402 | 21 157 (49 898) | 0.424 | .079 | |
| Inhibitory score (cutoff > 1.75) | 1 002 (1 676) | 0.598 | 28 741 (49 898) | 0.576 | ||
| Inhibitory and activating KIR/KIR-ligand matches∗(Rafei et al), overall χ2 test P = .164 | ||||||
| Inhibitory and activating favorable | 1 087 (1 581) | 0.688 | 29 695 (42 171) | 0.704 | .164 | |
| Inhibitory and activating unfavorable† | 494 (1 581) | 0.312 | 12 476 (42 171) | 0.296 | ||
| Nonweighted additive inhibitory/missing-ligand KIR score (Krieger et al), overall χ2 test P = .206 | ||||||
| 2 | 2 (1 584) | 0.001 | 61 (42 177) | 0.001 | 1.000 | 1.000 |
| 3 | 73 (1 584) | 0.046 | 2 483 (42 177) | 0.059 | .039 | .158 |
| 4 | 870 (1 584) | 0.550 | 22 780 (42 177) | 0.540 | .440 | 1.000 |
| 5 | 636 (1 584) | 0.402 | 16 853 (42 177) | 0.400 | .850 | 1.000 |
∗
The truncated version of KIR2DS4 is not considered as an activating KIR.
†
≥3 inhibitory KIR/KIR-ligand matches and no activating KIR/KIR-ligand match. Numbers of cases evaluated for each test vary because of remaining ambiguities and are reported in parentheses.